ai3Bio launches with $48 million Series A funding
The biotechnology company said the round was led by UPMC Enterprises and Ziff Capital Partners. Proceeds will support IND-enabling studies and first-in-human trials in autoimmune disease.
The biotechnology company said the round was led by UPMC Enterprises and Ziff Capital Partners. Proceeds will support IND-enabling studies and first-in-human trials in autoimmune disease.